Jenny Sundqvist appointed CEO of Navinci
Navinci’s Board of Directors is pleased to announce the appointment of Jenny Sundqvist as the new Chief Executive Officer, effective December 1, 2024.
Precision for Medicine and Navinci Announce Strategic Partnership
A partnership announced between Precision for Medicine and Navinci to offer isPLA as part of Precision for Medicine’s CRO services.
Navinci announces stepping down of CEO, Robert Gunnarsson
Navinci announces CEO Robert Gunnarsson’s resignation, with Agata Zieba-Wicher as interim leader while the board searches for a permanent successor.
Partnership announced between Canopy Biosciences and Navinci
A partnership announced between Canopy Biosciences and Navinci to offer isPLA as part of Canopy’s CRO services.
Leica Biosystems and Navinci Partner to Accelerate Cancer Research
Leica Biosystems, a global leader in anatomic pathology, and Navinci, announce a strategic collaboration to drive innovation in cancer patient care.
Navinci and Vector Labs announce strategic collaboration
Vector Laboratories and Navinci Diagnostics partner to pioneer biomarker discovery tools, enabling specific protein glycosylation detection in tissue samples, revolutionizing glycoproteomic research.
Navinci Diagnostics has partnered with Shanghai Universal Biotech
Navinci Diagnostics has entered into a partnership with Shanghai Universal Biotech, becoming our exclusive distributor for the Chinese market.
Navinci and Research Instruments announce a strategic partnership
Navinci have reached a distribution partnership with leading supplier of cutting-edge research and life science tools Everlife-Research Instruments.
Cayman and Navinci Announce Strategic Partnership
Cayman and Navinci Announce Strategic Partnership Expanding Access to Next-Generation Tools for Spatial Proteomics Ann Arbor, MI – 07/05/2023 – Global life sciences supplier Cayman Chemical (Cayman) announced today a strategic partnership with Navinci Diagnostics (Navinci), a Swedish biotechnology company developing innovative tools for spatial proteomics. This partnership expands access to Navinci’s portfolio of proximity…
Navinci Diagnostics announces the appointment of Dr Subham Basu as new Chief Business Officer
Press release Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the appointment of Dr Subham Basu as new Chief Business Officer, effective April 11th 2023. Dr Subham Basu will join Navinci to lead the organizational build-up and international commercialization of the unique Navinci product portfolio for Spatial…
Navinci Diagnostics AB appoints Eva Pisa as chairman, further strengthens the leadership team and establishes a Scientific Advisory Board
Navinci Diagnostics AB appoints Eva Pisa as chairman, further strengthens the leadership team, and establishes a Scientific Advisory Board In line with the company’s vision of becoming a leader in spatial proteomics, Navinci further strengthens its organization and is pleased to announce the appointment of Dr. Eva Pisa as new chairman of the board, Dr.…
Navinci Diagnostics AB announces closing of SEK 90M Series A financing, led by Segulah Medical Acceleration with support from existing shareholders
Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of a SEK 90 million financing round. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.…